The MarketWatch News Department was not involved in the creation of this content. -- Peer-reviewed data published in Neurosurgery show that SOLOPASS(R) 2.0 delivers significantly higher accuracy than ...
PLEASANTON, Calif. -- Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it has acquired the ...
Please provide your email address to receive an email when new articles are posted on . The FDA and Medtronic alerted health care providers to no longer implant patients with end-stage HF with a ...
LOWELL, Mass., May 22, 2018 /PRNewswire/ -- Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful ...
With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.
SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the ...
98% of placements using SOLOPASS® 2.0 entered the ventricular system, versus only 10% of freehand placements. 86% of placements using SOLOPASS® 2.0 accurately reached the ipsilateral frontal horn ...